Lupus Foundation of America Seeks Applications to Advance the Understanding of Lupus Nephritis

WASHINGTON--(BUSINESS WIRE)-- The Lupus Foundation of America (LFA) seeks grant applications from medical researchers to help advance the understanding of lupus nephritis, a serious and life-threatening complication of lupus that can affect as many as 40 percent of all people with lupus, and two-thirds of children with the disease.

Lupus nephritis is the term used when lupus causes inflammation in the kidneys, making them unable to properly remove waste from the blood or control the amount of fluids in the body. Left untreated, lupus nephritis can lead to scarring and permanent damage to the kidneys and possibly end-stage renal disease. There are often few symptoms of kidney disease.

The LFA is seeking applications that advance the science and understanding of lupus nephritis related to the development of biomarkers to measure disease activity, specialized treatment guidelines, quality of life measures for adults and children, and new therapeutic interventions for the treatment of lupus nephritis.

The grant is provided as part of the LFA’s National Research Program, Bringing Down the Barriers. The LFA has an ongoing commitment to advancing the science and medicine of lupus, developing new therapies, and finding a cure for lupus. Specifically, the LFA research program seeks to address gaps in understanding of lupus, and other areas of research not supported by other public and private institutions. Since its inception, the LFA and its affiliated chapters have provided nearly $23 million to fund more than 400 grants to research scientists at nearly 100 leading academic and medical institutions throughout the nation.

Binding letters of intent must be submitted by May 10, 2010. Online applications must be submitted by June 18, 2010. Awards will be announced on September 6, 2010. The LFA uses an electronic grant submission process and all interested grant applicants should submit their letters of intent and proposals via proposalCENTRAL at https://proposalcentral.altum.com/Login.asp. To learn more about the LFA’s National Research Program, Bringing Down the Barriers, visit www.lupus.org/research.

About Lupus

Lupus is an acute and chronic autoimmune disease in which the immune system is unbalanced, causing inflammation and tissue damage to virtually any organ in the body. Lupus can be unpredictable and potentially fatal, yet no satisfactory treatment or cure presently exists. An estimated 1.5 million Americans and at least five million people worldwide have a form of lupus. Its health effects include heart attacks, strokes, seizures, miscarriages, and organ failure.

About the LFA

The LFA is the nation’s foremost nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all people affected by lupus. The LFA and its network of chapters, branches, and support groups conduct programs of research, education, and advocacy.



CONTACT:

Lupus Foundation of America
Maggie Maloney, 202-212-6766
[email protected]
or
Duane Peters, 202-349-1145
[email protected]

KEYWORDS:   United States  North America  District of Columbia

INDUSTRY KEYWORDS:   Education  University  Health  Biotechnology  Genetics  Other Health  Research  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.